Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2013)

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2013)

Docket	1:13-cv-01467	Date Filed	2013-08-22
Court	District Court, D. Delaware	Date Terminated	2014-09-17
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,316,023; 6,335,031
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-08-22				External link to document

Novartis v. Par (1:13-cv-01467) Litigation Summary: Claims, Procedural Posture, and IP Exposure

Last updated: July 1, 2026

This litigation (Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc., No. 1:13-cv-01467) is a patent infringement dispute tied to Par’s generic development of a Novartis product for which Novartis asserted US patent rights. The case is used by both sides to test validity and infringement positions tied to the asserted Orange Book-listed patents, with procedural milestones centered on infringement pleadings, claim construction, dispositive motions, and resolution through final judgment and/or settlement-driven end states.

What patent estate did Novartis assert against Par in 1:13-cv-01467?

Featured snippet: Novartis asserted one or more US patents listed for the relevant Novartis drug in the Orange Book against Par’s proposed generic product. The infringement theory depends on whether Par’s submission and proposed manufacture fall within the asserted claims.

What the asserted claims typically cover in this case type

• Composition or formulation claims (active ingredient, specific composition, excipients, polymorphs, salts, or release characteristics)
• Method-of-use or method-of-manufacture claims (if the Orange Book listing or FDA submission ties to a dosing regimen or manufacturing step)
• Claims directed to dosage form design (strength, coating, controlled release, or bioequivalence-related performance attributes)

Key parties

• Plaintiff: Novartis Pharmaceuticals Corporation
• Defendant: Par Pharmaceutical Inc.
• Case number: 1:13-cv-01467

What patents were listed in the Orange Book for the Novartis drug at issue?

Featured snippet: The Orange Book listed patents corresponding to the Novartis NDA for the referenced product are the patents most directly implicated by the infringement allegations in this docket.

How Orange Book listings drive the lawsuit

• Novartis’s asserted patents track patents listed for the reference listed drug (RLD) on the Orange Book.
• Par’s FDA ANDA filing triggered the typical “compulsory counterclaims” framework under the Hatch-Waxman statute, allowing Par to challenge validity and/or non-infringement.

What procedural milestones shaped the outcome in 1:13-cv-01467?

Featured snippet: The case progressed through standard Hatch-Waxman infringement procedure, with early pleadings followed by claim construction and motions practice, then final resolution.

Typical docket flow in this category of cases

• Initial complaint and patent infringement allegations by Novartis
• ANDA-triggered procedural posture (timing tied to FDA submissions)
• Claim construction order(s)
• Summary judgment and/or dispositive motion briefing
• Final judgment and/or settlement disposition

What did claim construction determine in Novartis v. Par?

Featured snippet: Claim construction narrowed disputed claim terms and set the framework for infringement and validity analyses.

Where construction usually matters

• Interpreting claim scope for formulation terms (especially if the dispute hinges on whether Par’s generic composition matches the patentee’s claimed ranges or structural features)
• Interpreting method limitations (when Par’s proposed manufacturing or intended use is at issue)
• Interpreting functional limitations (where performance characteristics or test-defined endpoints can decide infringement)

How did Novartis argue infringement, and how did Par respond?

Featured snippet: Novartis argued Par’s ANDA product infringes one or more asserted claims; Par responded that the product does not meet the claim limitations and/or that the asserted claims are invalid.

Novartis’s infringement theory (typical for this docket type)

• Par’s proposed product meets all claim limitations as recited in the asserted US patents
• Par’s ANDA submission and proposed composition/dosage form map onto the claims

Par’s defenses (typical)

• Non-infringement based on differences in composition, formulation, dosage form, or method steps
• Invalidity challenges under § 102, § 103, and/or § 112 theories depending on the asserted patent’s basis
• On occasion, enforceability challenges, though invalidity and non-infringement dominate most Hatch-Waxman dockets

What validity challenges did Par raise against the asserted patents?

Featured snippet: Par typically challenged the asserted claims for lack of novelty, obviousness, and sometimes enablement or indefiniteness.

Validity issue buckets that usually appear

• Prior art novelty (anticipation) under § 102
• Obviousness under § 103 with cited references plus motivations
• Claim definiteness under § 112(b) when claim language is test- or parameter-driven
• Written description and enablement under § 112(a) when the specification’s support for the claimed scope is contested

Did the case end in judgment or settlement, and what was the impact?

Featured snippet: The docket disposition reflects the enforcement endpoint of the asserted Orange Book patents, either through a final adjudication or resolution that functionally bars or delays Par’s launch until the patent position is resolved.

Business impact of settlement-driven or judgment-driven end states

• If Novartis prevailed: Par’s launch typically delayed pending appeal window or until patent expiration/another resolution pathway
• If Par prevailed: Par could often proceed to launch sooner, subject to any additional patents not challenged in this docket
• If settlement: launch dates and “carve-outs” are often defined by patent expiration dates, agreed noninfringement positions, or delayed launch timelines

Which FDA/ANDA milestone timing aligns with this litigation?

Featured snippet: Hatch-Waxman timing links filing of the ANDA and the litigation timeline to the “30-month stay” structure, with resolution affecting whether the generic can launch.

How to map litigation to exclusivity risk

• If the case resolved before the 30-month date, the effective launch date depends on the final injunction scope and any settlement terms
• If the case continued beyond typical stay windows, the generic entry depends on final judgment or negotiated settlement terms

What generic entry risks did Novartis preserve through this case?

Featured snippet: By litigating asserted Orange Book patents, Novartis preserved exclusivity-like leverage against early ANDA launch.

How this case reduces generic entry risk

• Patent injunction leverage: if infringement was found and injunction issued, Par launch would be barred
• Validity leverage: if asserted claims were upheld, later attempts to design around become more constrained
• Exclusivity fragmentation: other patents (not asserted here) can still create launch friction even after resolving this docket

How does Par’s litigation posture in 1:13-cv-01467 compare with other Par generic challenges?

Featured snippet: This docket fits the pattern where Par challenges Orange Book patents covering Novartis RLD products, with defenses clustered around non-infringement and invalidity.

Common strategic patterns

• Targeting claim elements that are sensitive to formulation differences (ranges, polymorph identity, or release attributes)
• Attacking patents with the broadest claim language first, since that tends to yield the strongest leverage for non-infringement and invalidity

Does this litigation map to broader Novartis patent strategy for that drug class?

Featured snippet: The case reflects enforcement of a specific patent bundle tied to a Novartis RLD, often spanning formulation and/or method-of-use.

Strategic signals

• Novartis concentrated asserted claims into a litigation bundle designed to block generic entry through overlapping IP coverage
• Par’s response tested both infringement mapping and patent validity, which is central to whether generic launch becomes feasible

Key takeaways on 1:13-cv-01467 for licensing, R&D, and entry strategy

• The case is a Hatch-Waxman style patent dispute between Novartis and Par, anchored to Orange Book-listed US patents.
• The litigation’s practical value is that it resolves (via judgment or settlement) whether Par can launch its ANDA product before asserted patents expire.
• The strongest commercial lesson for market entrants is the need to map proposed generic compositions and manufacturing steps onto each asserted claim element and to underwrite the prior-art and enablement/definiteness risks.
• For Novartis, the case functioned as IP enforcement leverage that either delayed entry or preserved patent value through adjudicated or negotiated outcomes.

---

FAQs

What is the jurisdiction and docket source for Novartis v. Par (1:13-cv-01467)?

Federal district litigation under the case number 1:13-cv-01467.

What is the legal basis for the infringement dispute in this docket?

Hatch-Waxman patent infringement claims tied to Par’s ANDA and the Orange Book-listed patents for the Novartis reference product.

What usually happens to generic launch timing after this type of case?

Launch timing typically turns on whether the patents are upheld, invalidated, or resolved through settlement.

Which patent issues decide these cases most often?

Claim scope through claim construction, then infringement mapping; if those fail, validity challenges (anticipation/obviousness and related § 112 issues) become decisive.

How does settlement in these dockets typically affect entry?

Settlements commonly set negotiated entry dates and may include carve-outs affecting whether a generic can launch immediately on resolution.

---

References (APA)

1. US District Court docket, Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc., No. 1:13-cv-01467.